Stock Snapshot from
United Therapeutics CorpAdd to My Watchlist
UTHR:USNASDAQ GSIndustry: Medical-Biomedical/Gene
- 66.89Last
- 0.93 -1.37%Today's Change
- 68.47Previous Close
- 52 Week Low - High
Earnings
| EPS: Year Actual ttm | 5.296 |
| EPS: Year Est. 12/13 ttm | 8.333 |
| EPS: Quarterly Actual 3/13 | 2.65 |
| EPS: Quarterly Est. 6/13 | 2.06 |
| Price/Earnings ttm | 12.65 |
| Relative Price/Earnings | 0.783 |
| Earnings Growth Rate | 53.68 |
Company Description
| United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials. | |
| Revenue | $916 million |
| Net Income | $304 million |
| Total Assets | $2 billion |
| Employees | 543 |
| Web Site | www.unither.com |
Latest Headlines
Watchlist
Unless indicated otherwise: intraday data is at least 15 minutes delayed; mutual fund NAVs are updated at the close of every market day; all prices are in the local currency; Time is ET.